Machine Learning Identification and Animal Model Validation of Key Genes for Lipid Metabolism in Diabetic Nephropathy

Yue LI, Yuyu ZHANG, Xing WAN, Songlin NIU, Honghong SHI, Lihua WANG

Acta Academiae Medicinae Sinicae ›› 2025, Vol. 47 ›› Issue (6) : 873-887.

PDF(5521 KB)
Home Journals Acta Academiae Medicinae Sinicae
Acta Academiae Medicinae Sinicae

Abbreviation (ISO4): Acta Academiae Medicinae Sinicae      Editor in chief: Xuetao CAO

About  /  Aim & scope  /  Editorial board  /  Indexed  /  Contact  / 
PDF(5521 KB)
Acta Academiae Medicinae Sinicae ›› 2025, Vol. 47 ›› Issue (6) : 873-887. DOI: 10.3881/j.issn.1000-503X.16594
Original Articles

Machine Learning Identification and Animal Model Validation of Key Genes for Lipid Metabolism in Diabetic Nephropathy

Author information +
History +

Abstract

Objective To identify key genes of lipid metabolism in diabetic nephropathy(DN) through machine learning models and animal model validation. Methods The limma R package was used for differential gene expression analysis on 69 samples from two transcriptome datasets of the Gene Expression Omnibus and 2 184 differentially expressed genes were identified.Subsequently,we adopted undifferentiated consensus clustering to classify DN samples into two specific subtypes.At the same time,we performed weighted gene co-expression network analysis to mine the gene modules significantly associated with DN.In addition,using least absolute shrinkage and selection operator,support vector machine-recursive feature elimination,and random forest machine learning techniques,combined with protein-protein interaction network analysis,we screened out three core genes.Finally,we constructed a mouse model of type 2 diabetes mellitus to verify the effectiveness of the expression of these key genes. Results Three core genes,APOO,ALDH7A1,and ALB,were predicted as potential biomarkers of lipid metabolism in DN,and their expression levels were downregulated in DN.Through experimental validation in a diabetic mouse model,we confirmed the altered expression of APOO,ALDH7A1,and ALB in DN,which supported their potential as diagnostic markers. Conclusions Our findings suggest that APOO,ALDH7A1,and ALB are new diagnostic markers associated with lipid metabolism in DN,which provides new perspectives for understanding the molecular mechanisms of lipid metabolism in DN.

Key words

diabetic nephropathy / lipid metabolism / machine learning / biomarkers / bioinformatics

Cite this article

Download Citations
Yue LI , Yuyu ZHANG , Xing WAN , et al . Machine Learning Identification and Animal Model Validation of Key Genes for Lipid Metabolism in Diabetic Nephropathy[J]. Acta Academiae Medicinae Sinicae. 2025, 47(6): 873-887 https://doi.org/10.3881/j.issn.1000-503X.16594

References

[1]
Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus[J]. N Engl J Med, 1999, 341(15):1127-1133.DOI:10.1056/NEJM199910073411506.
[2]
Fineberg D, Jandeleit-Dahm KA, Cooper ME. Diabetic nephropathy:diagnosis and treatment[J]. Nat Rev Endocrinol, 2013, 9(12):713-723.DOI:10.1038/nrendo.2013.184.
[3]
Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy:diagnosis,prevention,and treatment[J]. Diabetes Care, 2005, 28(1):164-176.DOI:10.2337/diacare.28.1.164.
[4]
Han YZ, Du BX, Zhu XY, et al. Lipid metabolism disorder in diabetic kidney disease[J]. Front Endocrinol(Lausanne), 2024, 15:1336402.DOI:10.3389/fendo.2024.1336402.
[5]
Herman-Edelstein M, Scherzer P, Tobar A, et al. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy[J]. J Lipid Res, 2014, 55(3):561-572.DOI:10.1194/jlr.P040501.
[6]
Jiang T, Wang XX, Scherzer P, et al. Farnesoid X receptor modulates renal lipid metabolism,fibrosis,and diabetic nephropathy[J]. Diabetes, 2007, 56(10):2485-2493.DOI:10.2337/db06-1642.
[7]
Wang Y, Liu T, Wu Y, et al. Lipid homeostasis in diabetic kidney disease[J]. Int J Biol Sci, 2024, 20(10):3710-3724.DOI:10.7150/ijbs.95216.
[8]
Yang M, Luo S, Yang J, et al. Lipid droplet-mitochondria coupling:a novel lipid metabolism regulatory hub in diabetic nephropathy[J]. Front Endocrinol(Lausanne), 2022, 13:1017387.DOI:10.3389/fendo.2022.1017387.
[9]
Thongnak L, Pongchaidecha A, Lungkaphin A. Renal lipid metabolism and lipotoxicity in diabetes[J]. Am J Med Sci, 2020, 359(2):84-99.DOI:10.1016/j.amjms.2019.11.004.
[10]
Gai Z, Wang T, Visentin M, et al. Lipid accumulation and chronic kidney disease[J]. Nutrients, 2019, 11(4):722.DOI:10.3390/nu11040722.
[11]
Izquierdo-Lahuerta A, Martínez-García C, Medina-Gómez G. Lipotoxicity as a trigger factor of renal disease[J]. J Nephrol, 2016, 29(5):603-610.DOI:10.1007/s40620-016-0278-5.
[12]
Njeim R, Alkhansa S, Fornoni A. Unraveling the crosstalk between lipids and NADPH oxidases in diabetic kidney disease[J]. Pharmaceutics, 2023, 15(5):1360.DOI:10.3390/pharmaceutics15051360.
[13]
Opazo-Ríos L, Mas S, Marín-Royo G, et al. Lipotoxicity and diabetic nephropathy:novel mechanistic insights and therapeutic opportunities[J]. Int J Mol Sci, 2020, 21(7):2632.DOI:10.3390/ijms21072632.
[14]
Kim Y, Lim JH, Kim MY, et al. The adiponectin receptor agonist adiporon ameliorates diabetic nephropathy in a model of type 2 diabetes[J]. J Am Soc Nephrol, 2018, 29(4):1108-1127.DOI:10.1681/ASN.2017060627.
[15]
Zhang X, Chao P, Zhang L, et al. Single-cell RNA and transcriptome sequencing profiles identify immune-associated key genes in the development of diabetic kidney disease[J]. Front Immunol, 2023, 14:1030198.DOI:10.3389/fimmu.2023.1030198.
[16]
Hu K, He R, Xu M, et al. Identification of necroptosis-related features in diabetic nephropathy and analysis of their immune microenvironent and inflammatory response[J]. Front Cell Dev Biol, 2023, 11:1271145.DOI:10.3389/fcell.2023.1271145.
[17]
Ming J, Sana SRGL, Deng X. Identification of copper-related biomarkers and potential molecule mechanism in diabetic nephropathy[J]. Front Endocrinol(Lausanne), 2022, 13:978601.DOI:10.3389/fendo.2022.978601.
[18]
Li Z, Feng J, Zhong J, et al. Screening of the key genes and signalling pathways for diabetic nephropathy using bioinformatics analysis[J]. Front Endocrinol(Lausanne), 2022, 13:864407.DOI:10.3389/fendo.2022.864407.
[19]
Yang J, Peng L, Tian Y, et al. Identification of hub genes involved in tubulointerstitial injury in diabetic nephropathy by bioinformatics analysis and experiment verification[J]. J Immunol Res, 2022, 2022:7907708.DOI:10.1155/2022/7907708.
[20]
Zhang H, Hu J, Zhu J, et al. Machine learning-based metabolism-related genes signature and immune infiltration landscape in diabetic nephropathy[J]. Front Endocrinol(Lausanne), 2022, 13:1026938.DOI:10.3389/fendo.2022.1026938.
[21]
Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies[J]. Nucleic Acids Res, 2015, 43(7):e47.DOI:10.1093/nar/gkv007.
[22]
Wilkerson MD, Hayes DN. ConsensusClusterPlus:a class discovery tool with confidence assessments and item tracking[J]. Bioinformatics, 2010, 26(12):1572-1573.DOI:10.1093/bioinformatics/btq170.
[23]
Langfelder P, Horvath S. WGCNA:an R package for weighted correlation network analysis[J]. BMC Bioinformatics, 2008, 9:559.DOI:10.1186/1471-2105-9-559.
[24]
Lin X, Li C, Zhang Y, et al. Selecting feature subsets based on SVM-RFE and the overlapping ratio with applications in bioinformatics[J]. Molecules, 2017, 23(1):52.DOI:10.3390/molecules23010052.
[25]
Uddin S, Khan A, Hossain ME, et al. Comparing different supervised machine learning algorithms for disease prediction[J]. BMC Med Inform Decis Mak, 2019, 19(1):281.DOI:10.1186/s12911-019-1004-8.
[26]
Fornes O, Castro-Mondragon JA, Khan A, et al. JASPAR 2020:update of the open-access database of transcription factor binding profiles[J]. Nucleic Acids Res, 2020, 48(D1):D87-D92.DOI:10.1093/nar/gkz1001.
[27]
Yoo M, Shin J, Kim J, et al. DSigDB:drug signatures database for gene set analysis[J]. Bioinformatics, 2015, 31(18):3069-3071.DOI:10.1093/bioinformatics/btv313.
[28]
Zhou G, Soufan O, Ewald J, et al. NetworkAnalyst 3.0:a visual analytics platform for comprehensive gene expression profiling and meta-analysis[J]. Nucleic Acids Res, 2019, 47(W1):W234-W241.DOI:10.1093/nar/gkz240.
[29]
Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes[J]. N Engl J Med, 2015, 373(18):1720-1732.DOI:10.1056/NEJMoa1504347.
[30]
Brennan E, Kantharidis P, Cooper ME, et al. Pro-resolving lipid mediators:regulators of inflammation,metabolism and kidney function[J]. Nat Rev Nephrol, 2021, 17(11):725-739.DOI:10.1038/s41581-021-00454-y.
[31]
Jaiswal M, Schinske A, Pop-Busui R. Lipids and lipid management in diabetes[J]. Best Pract Res Clin Endocrinol Metab, 2014, 28(3):325-338.DOI:10.1016/j.beem.2013.12.001.
[32]
Wang Y, Liu T, Cai Y, et al. SIRT6’s function in controlling the metabolism of lipids and glucose in diabetic nephropathy[J]. Front Endocrinol(Lausanne), 2023, 14:1244705.DOI:10.3389/fendo.2023.1244705.
[33]
Ducasa GM, Mitrofanova A, Fornoni A. Crosstalk between lipids and mitochondria in diabetic kidney disease[J]. Curr Diab Rep, 2019, 19(12):144.DOI:10.1007/s11892-019-1263-x.
[34]
Li Z, Guo H, Li J, et al. Sulforaphane prevents type 2 diabetes-induced nephropathy via AMPK-mediated activation of lipid metabolic pathways and Nrf2 antioxidative function[J]. Clin Sci(Lond), 2020, 134(18):2469-2487.DOI:10.1042/CS20191088.
[35]
Lamant M, Smih F, Harmancey R, et al. ApoO,a novel apolipoprotein,is an original glycoprotein up-regulated by diabetes in human heart[J]. J Biol Chem, 2006, 281(47):36289-36302.DOI:10.1074/jbc.M510861200.
[36]
Chen J, Hu J, Guo X, et al. Apolipoprotein O modulates cholesterol metabolism via NRF2/CYB5R3 independent of LDL receptor[J]. Cell Death Dis, 2024, 15(6):389.DOI:10.1038/s41419-024-06778-4.
[37]
Guo X, Hu J, He G, et al. Loss of APOO(MIC26) aggravates obesity-related whitening of brown adipose tissue via PPARα-mediated functional interplay between mitochondria and peroxisomes[J]. Metabolism, 2023, 144:155564.DOI:10.1016/j.metabol.2023.155564.
[38]
Turkieh A, Caubère C, Barutaut M, et al. Apolipoprotein O is mitochondrial and promotes lipotoxicity in heart[J]. J Clin Invest, 2014, 124(5):2277-2286.DOI:10.1172/JCI74668.
[39]
Yu BL, Wu CL, Zhao SP. Plasma apolipoprotein O level increased in the patients with acute coronary syndrome[J]. J Lipid Res, 2012, 53(9):1952-1957.DOI:10.1194/jlr.P023028.
[40]
Wu CL, Zhao SP, Yu BL. Microarray analysis provides new insights into the function of apolipoprotein O in HepG2 cell line[J]. Lipids Health Dis, 2013, 12:186.DOI:10.1186/1476-511X-12-186.
[41]
Sun J, Zhang X, Wang S, et al. Dapagliflozin improves podocytes injury in diabetic nephropathy via regulating cholesterol balance through KLF5 targeting the ABCA1 signalling pathway[J]. Diabetol Metab Syndr, 2024, 16(1):38.DOI:10.1186/s13098-024-01271-6.
[42]
Lee JS, Lee H, Woo SM, et al. Overall survival of pancreatic ductal adenocarcinoma is doubled by Aldh7a1 deletion in the KPC mouse[J]. Theranostics, 2021, 11(7):3472-3488.DOI:10.7150/thno.53935.
[43]
Yang JS, Hsu JW, Park SY, et al. ALDH7A1 inhibits the intracellular transport pathways during hypoxia and starvation to promote cellular energy homeostasis[J]. Nat Commun, 2019, 10(1):4068.DOI:10.1038/s41467-019-11932-0.
[44]
Brocker C, Lassen N, Estey T, et al. Aldehyde dehydrogenase 7A1(ALDH7A1) is a novel enzyme involved in cellular defense against hyperosmotic stress[J]. J Biol Chem, 2010, 285(24):18452-18463.DOI:10.1074/jbc.M109.077925.
[45]
Chen CH, Ferreira JC, Gross ER, et al. Targeting aldehyde dehydrogenase 2:new therapeutic opportunities[J]. Physiol Rev, 2014, 94(1):1-34.DOI:10.1152/physrev.00017.2013.
[46]
Marchitti SA, Brocker C, Stagos D, et al. Non-P450 aldehyde oxidizing enzymes:the aldehyde dehydrogenase superfamily[J]. Expert Opin Drug Metab Toxicol, 2008, 4(6):697-720.DOI:10.1517/17425255.4.6.697.
[47]
Vasiliou V, Thompson DC, Smith C, et al. Aldehyde dehydrogenases:from eye crystallins to metabolic disease and cancer stem cells[J]. Chem Biol Interact, 2013, 202(1-3):2-10.DOI:10.1016/j.cbi.2012.10.026.
[48]
Marchitti SA, Deitrich RA, Vasiliou V. Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde:the role of aldehyde dehydrogenase[J]. Pharmacol Rev, 2007, 59(2):125-150.DOI:10.1124/pr.59.2.1.
[49]
Brocker C, Cantore M, Failli P, et al. Aldehyde dehydrogenase 7A1(ALDH7A1) attenuates reactive aldehyde and oxidative stress induced cytotoxicity[J]. Chem Biol Interact, 2011, 191(1-3):269-277.DOI:10.1016/j.cbi.2011.02.016.
[50]
Fu X, Yang Y, Zhang D. Molecular mechanism of albumin in suppressing invasion and metastasis of hepatocellular carcinoma[J]. Liver Int, 2022, 42(3):696-709.DOI:10.1111/liv.15115.
[51]
Chen L, Wei W, Sun J, et al. Cordycepin enhances anti-tumor immunity in breast cancer by enhanceing ALB expression[J]. Heliyon, 2024, 10(9):e29903.DOI:10.1016/j.heliyon.2024.e29903.
[52]
Agrawal S, Guess AJ, Chanley MA, et al. Albumin-induced podocyte injury and protection are associated with regulation of COX-2[J]. Kidney Int, 2014, 86(6):1150-1160.DOI:10.1038/ki.2014.196.
PDF(5521 KB)

Accesses

Citation

Detail

Sections
Recommended

/